In addition , 19 letters to the editor/ review s/editorials/experts ' surveys/experts ' opinion were used for discussion purpose s. Conclusions NVAF is highly prevalent among ICH survivors .
The risks of IS , recurrent ICH , and mortality are heightened in this group .
Most published data show a net benefit in terms of IS prevention and mortality when anticoagulation is restarted .
Background We summarize the existing evidence on the potential benefit of oral anticoagulation ( OAC ) in intracerebral hemorrhage ( ICH ) survivors with nonvalvular atrial fibrillation ( NVAF ) .
Variation in Restarting Antithrombotic Drugs at Hospital Discharge After Intracerebral Hemorrhage
Background and Purpose — Whether intracerebral hemorrhage ( ICH ) survivors should restart antithrombotic drugs is unknown . We analyzed the frequency of restarting antithrombotic drugs  in ICH survivors who had taken prophylactic antithrombotic drugs in atrial fibrillation or after thromboembolic disease in 5 cohorts and explored factors associated with doing so . Methods — We compared the characteristics and proportions of patients taking antithrombotic drugs at ICH onset and discharge in 4 hospital-based cohorts ( Lille , France , n=542 ; Utrecht , The Netherl and s , n=389 ; multicenter Clinical Relevance of Microbleeds in Stroke-2 ( CROMIS-2 ) ICH , United Kingdom , n=667 ; and Amsterdam , The Netherl and s , n=403 ) and 1 community-based study ( Lothian , Scotl and , n=137 ) , using bivariate analyses . We sought characteristics associated with restarting using bivariate and multivariable logistic regression analyses . Results — A total of 942 ( 44 % ) patients with ICH took  antithrombotic drugs  at hospital admission ( no difference between cohorts ) .  Antithrombotic drugs  were restarted in 96 ( 20 % ) of the 469 survivors who had taken antithrombotic drugs for secondary prevention or atrial fibrillation , but this proportion differed when stratified by the cohort of origin ( Lille , 18 % ; Utrecht , 45 % ; Lothian , 15 % ; CROMIS-2 ICH , 11 % ; Amsterdam , 20 % ; P<0.001 ) and by type of antithrombotic drug pre-ICH ( 14 % in patients with previous antiplatelet drugs versus 26 % in patients with previous vitamin K antagonists and 41 % in patients with both drugs ; P<0.001 ) . We did not find other consistent , independent associations with restarting antithrombotic drugs . Conclusions — The variation in clinical practice and lack of consistent associations with restarting antithrombotic drugs after ICH reflect current knowledge and support the need for r and omized controlled trials to resolve this dilemma
In addition , 19 letters to the editor/ review s/editorials/experts ' surveys/experts ' opinion were used for discussion purpose s. Conclusions NVAF is highly prevalent among ICH survivors .
The risks of IS , recurrent ICH , and mortality are heightened in this group .
Most published data show a net benefit in terms of IS prevention and mortality when anticoagulation is restarted .
Background We summarize the existing evidence on the potential benefit of oral anticoagulation ( OAC ) in intracerebral hemorrhage ( ICH ) survivors with nonvalvular atrial fibrillation ( NVAF ) .